Evofem Biosciences v. Padagis: Voluntary Dismissal After 75 Days
Evofem Biosciences and its affiliates filed a patent infringement action against Padagis Israel Pharmaceuticals and related entities in Delaware, asserting three patents covering contraceptive microbicide compositions and alginic acid-based antimicrobial methods. The case was voluntarily dismissed without prejudice just 75 days after filing.
Early exit: Evofem drops three-patent microbicide suit against Padagis
On 2 June 2023, Evofem Biosciences, Inc., Evofem, Inc., and Evofem Biosciences Operations, Inc. filed a patent infringement action in the District of Delaware against Padagis Israel Pharmaceuticals Limited, Padagis LLC, and Padagis US LLC. The complaint asserted three patents — US10568855B2, US11439610B2, and US11337989B2 — covering compositions and methods for enhancing the efficacy of contraceptive microbicides and alginic acid-based antimicrobial compounds for inhibiting inflammation.
The recorded basis of termination is voluntary dismissal. The docket order states that plaintiffs, pursuant to Fed. R. Civ. P. 41(a)(1)(A)(i), voluntarily dismissed all claims against defendants without prejudice. Rule 41(a)(1)(A)(i) permits a plaintiff to dismiss without a court order before the defendant has served an answer or a motion for summary judgment. The specific reasons for the dismissal are not disclosed in the available record.
The case closed on 16 August 2023, just 75 days after filing — a timeline consistent with early resolution before any substantive court engagement. Whether the dismissal reflects ongoing negotiations, a strategic pivot, or a business-driven decision by Evofem is not disclosed in the public record. Because the dismissal is without prejudice, Evofem retains the ability to refile these claims, subject to applicable statutes of limitations and any agreements between the parties that are not publicly disclosed.
See Complete Case & Patent Analysis →Filing to Voluntary dismissal in 75 days
75 days from filing to voluntary dismissal — resolved before substantive motions practice
US10568855B2, US11439610B2 & US11337989B2 — contraceptive microbicide and antimicrobial compositions
Any company developing or commercialising contraceptive microbicide formulations, alginic acid-based antimicrobial products, or adjacent women's health compounds should assess freedom-to-operate against all three Evofem patents. The without-prejudice dismissal means Evofem retains enforcement rights, and the absence of any claim-scope ruling from the court leaves the boundary of these patents' reach uncharted. Generic pharmaceutical entrants facing potential ANDA-related exposure are particularly exposed.
Official order — verbatim text
The dismissal notice invokes Rule 41(a)(1)(A)(i) and specifies that all claims are withdrawn without prejudice. This procedural mechanism requires no defendant consent and no court order, and it leaves no merits determination on the record. The absence of any judicial ruling on infringement, validity, or claim scope means neither party received a substantive legal finding — a neutral procedural exit whose underlying drivers are not disclosed in the available record.
Voluntarily dismissed: what the without-prejudice exit means for both parties
Rule 41(a)(1)(A)(i): plaintiff's unilateral exit right
Fed. R. Civ. P. 41(a)(1)(A)(i) allows a plaintiff to dismiss its own action without a court order, and without the defendant's consent, provided the defendant has not yet served an answer or a motion for summary judgment. This is the most procedurally straightforward dismissal route available in US federal practice. It requires no judicial approval and takes effect upon filing of the notice.
No court order requiredWithout prejudice: claims survive, future filing possible
The dismissal notice expressly states 'without prejudice', meaning Evofem's patent claims are not extinguished. Evofem retains the right to refile infringement claims on the same patents against Padagis, subject to applicable statutes of limitations. A dismissal without prejudice differs materially from one with prejudice, which would bar refiling. The specific terms or conditions — if any — that accompanied this dismissal are not disclosed in the available public record.
Claims not extinguishedPadagis escapes judgment — but uncertainty remains
The without-prejudice dismissal means no judgment, injunction, or liability finding has been entered against Padagis or its affiliates. However, Padagis cannot treat the litigation risk as fully resolved: without prejudice allows Evofem to refile. Padagis's commercial position in contraceptive microbicide products may remain under potential challenge unless the parties have reached a private arrangement not reflected in the public docket.
No judgment against defendantThree asserted patents remain active and enforceable
US10568855B2, US11439610B2, and US11337989B2 remain in force and were not invalidated or narrowed by this proceeding. Companies active in contraceptive microbicide formulation, alginic acid-based antimicrobial compositions, or adjacent women's health product development should monitor these patents' status and Evofem's filing activity. The early dismissal provides no claim-scope guidance from the court.
Patents remain enforceableFull party and counsel information
| Role | Name | Type | Detail |
|---|---|---|---|
| Plaintiff | Evofem Biosciences, Inc. | Company | /Search in Eureka ↗ |
| Co-Plaintiff | Evofem Biosciences Operations, Inc. | Company | Search in Eureka ↗ |
| Co-Plaintiff | Evofem, Inc. | Company | Search in Eureka ↗ |
| Defendant | Padagis Israel Pharmaceuticals Limited | Company | /Search in Eureka ↗ |
| Co-Defendant | Padagis, LLC | Company | Search in Eureka ↗ |
| Co-Defendant | Padagis US, LLC | Company | Search in Eureka ↗ |
| Plaintiff counsel | Christopher Viceconte | Attorney | Counsel for Evofem Biosciences, Inc.Search in Eureka ↗ |
| Plaintiff law firm | Gibbons PC | Law Firm | Representing Evofem Biosciences, Inc.Search in Eureka ↗ |
| Presiding judge | Judge Colm F. Connolly | Judge | Delaware District CourtSearch in Eureka ↗ |
R&D signals in contraceptive microbicide and antimicrobial biopolymer IP
Forward-looking patent and innovation intelligence derived from Evofem's asserted portfolio and the competitive landscape in women's health pharmaceutical formulation.
Evofem's continuation strategy in microbicide IP
Evofem holds at least three granted patents with distinct application lineages (US16/239314, US16/738868, US15/106755), suggesting an active continuation filing programme. Monitoring downstream divisionals and continuations from these families may reveal where Evofem is seeking to extend claim coverage — particularly around formulation methods and dosage forms in the contraceptive microbicide space.
Continuation family watchFiling trends in alginic acid-based antimicrobial formulations
Alginic acid and polysaccharide-based antimicrobial compounds are an active area of pharmaceutical innovation, with applications spanning women's health, wound care, and infection control. Patent filing activity in this domain signals competitive interest from both speciality pharma and generic manufacturers. Mapping the filing landscape around US11337989B2 may surface competing approaches and potential design-around opportunities.
Biopolymer antimicrobial trendPadagis's patent activity in pharmaceutical formulations
Padagis, operating through Israeli and US entities, is active in generic and speciality pharmaceutical manufacturing. Reviewing Padagis's own patent filings and any regulatory submissions in the contraceptive or antimicrobial segment may reveal the scope of its product pipeline and whether its activities remain within the risk perimeter of Evofem's patents post-dismissal.
Generic pharma IP watchAdjacent innovation opportunities in microbicide delivery systems
Evofem's patents focus on composition and method claims for contraceptive microbicide efficacy. Adjacent white space may exist in novel delivery formats — topical gels, intravaginal rings, or nanoparticle-based carriers — where coverage is less dense. R&D teams exploring next-generation women's health products may find patentable differentiation in delivery mechanism rather than active compound claims.
Delivery system white spaceSimilar patent infringement cases in contraceptive and antimicrobial pharma
Explore related patent infringement actions involving contraceptive formulations, microbicide compositions, and antimicrobial compounds filed in the District of Delaware and comparable pharmaceutical IP venues.
What this case signals for the women's health pharmaceutical IP landscape
A 75-day voluntary dismissal in a three-patent pharma suit raises questions about portfolio enforcement strategy and competitive dynamics in the microbicide space.
Without-prejudice dismissal keeps Evofem's enforcement options open
Evofem's Rule 41(a)(1)(A)(i) exit preserves all three patent claims for potential refiling. Competitors and generic manufacturers in the contraceptive microbicide space should treat these patents as live enforcement risks and ensure their freedom-to-operate analyses remain current.
No invalidity or claim-scope ruling creates continued ambiguity for the sector
Because the case was dismissed before any substantive court engagement, the scope and validity of US10568855B2, US11439610B2, and US11337989B2 remain untested. Product teams working in alginic acid-based antimicrobial or contraceptive microbicide formulations carry unresolved exposure until these patents are either litigated to a merits decision or expire.
Evofem v Padagis — key questions answered
Evofem asserted three patents: US10568855B2, US11439610B2, and US11337989B2. These cover compositions and methods for enhancing contraceptive microbicide efficacy and alginic acid-based antimicrobial compounds for inhibiting inflammation.
The available public record does not disclose the reasons for the dismissal. Evofem filed a Rule 41(a)(1)(A)(i) notice of voluntary dismissal without prejudice on 16 August 2023, 75 days after filing. The underlying drivers — whether commercial, strategic, or otherwise — are not stated in the docket.
A dismissal without prejudice does not extinguish Evofem's claims. Evofem retains the right to refile infringement claims on the same three patents against Padagis, subject to applicable statutes of limitations. No judgment, liability finding, or injunction was entered against either party.
No. The voluntary dismissal resulted in no court ruling on validity, infringement, or claim scope. US10568855B2, US11439610B2, and US11337989B2 remain in force and were not narrowed or invalidated by this proceeding. Third parties cannot rely on this case as precedent for any claim-scope determination.
Three Padagis entities were named: Padagis Israel Pharmaceuticals Limited (the primary defendant), Padagis LLC, and Padagis US LLC. All claims against all three entities were dismissed without prejudice by the plaintiff.
This page is compiled from public court dockets and third-party patent and litigation data via PatSnap Eureka, and is provided for general informational purposes only. The information shown — including party names, patent and application numbers, dates, case status, outcomes, and any analysis — may be incomplete, may not reflect the most recent filings or legal status, and may contain errors or omissions. Verify all details against official court records (for example, PACER) and the relevant patent office before relying on them.
Nothing on this page constitutes legal advice or a legal opinion on the validity, infringement, enforceability, or scope of any patent or case, and no attorney‑client relationship is created by its use. Any description of an outcome (such as a dismissal, settlement, or consent judgment) is a general summary, not a legal determination. All patents, trademarks, and company or law‑firm names are the property of their respective owners. PatSnap makes no warranty as to the accuracy or completeness of this content and disclaims, to the fullest extent permitted by law, all liability for reliance on it. For advice on a specific matter, consult qualified legal counsel.
PatSnap Eureka searches patents and litigation data to answer instantly.